Clinical Research Directory
Browse clinical research sites, groups, and studies.
Impact of Dapagliflozin in Anemic Chronic Kidney Disease Patients
Sponsor: Mansoura University
Summary
Dapagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor, primarily used in the management of type 2 diabetes mellitus. Emerging research suggests that SGLT2 inhibitors may offer additional benefits, including reducing the risk of cardiovascular events and renal complications. Post hoc analyses of previous clinical trials have shown that patients treated with SGLT2 inhibitors exhibited higher levels of hemoglobin and hematocrit compared to those in the control group. These findings suggest that dapagliflozin's ability to elevate hemoglobin levels could potentially be utilized for the treatment of anemia in patients with chronic kidney disease.
Official title: Clinical Study Evaluating the Impact of Dapagliflozin on Erythropoiesis-Stimulating Agent Responsiveness in Anemic Patients With Chronic Kidney Disease
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
80
Start Date
2025-04-01
Completion Date
2025-10
Last Updated
2025-04-02
Healthy Volunteers
No
Interventions
Dapagliflozin (DAPA)
Dapagliflizin 10 mg tablets once daily for 12 weeks
Erythropoiesis Stimulating Agent
Erythropoiesis stimulating agent (ESA) therapy
Locations (1)
Urology and Nephrology Center
Al Mansurah, Egypt